NCT03382418View on ClinicalTrials.gov

Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 27, 2017

Primary Completion Date

September 25, 2019

Study Completion Date

September 25, 2019

Conditions
HIV Infections
Interventions
BIOLOGICAL

gp145 C.6980 Vaccine

Administered by intramuscular injection in the deltoid.

BIOLOGICAL

Placebo

Sodium Chloride for Injection, 0.9%; Administered by intramuscular injection in the deltoid.

BIOLOGICAL

Aluminum Hydroxide Adjuvant

Administered by intramuscular injection in the deltoid.

Trial Locations (3)

10065

New York Blood Center CRS, New York

19104

Penn Prevention CRS, Philadelphia

10032-3732

Columbia P&S CRS, New York

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03382418 - Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States | Biotech Hunter | Biotech Hunter